Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3057% above fair value
$251.41+0.62 (+0.25%)
Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –
Biogen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biogen's operating income for the twelve months ending Mar 31, 2022 was $2.48B, down 33.1% year over year. For fiscal 2021 it was $2.84B, down 37.6% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $7.04B in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.84B | -37.6% |
| FY2020 | Dec 31, 2020 | $4.55B | -35.4% |
| FY2019 | Dec 31, 2019 | $7.04B | +19.6% |
| FY2018 | Dec 31, 2018 | $5.89B | +10.2% |
| FY2017 | Dec 31, 2017 | $5.35B | +3.8% |
| FY2016 | Dec 31, 2016 | $5.15B | +5.3% |
| FY2015 | Dec 31, 2015 | $4.89B | +23.1% |
| FY2014 | Dec 31, 2014 | $3.97B | +57.9% |
| FY2013 | Dec 31, 2013 | $2.52B | +35.5% |
| FY2012 | Dec 31, 2012 | $1.86B | +7.6% |
| FY2011 | Dec 31, 2011 | $1.72B | +38.1% |
| FY2010 | Dec 31, 2010 | $1.25B | -3.6% |
| FY2009 | Dec 31, 2009 | $1.30B | +6.7% |
| FY2008 | Dec 31, 2008 | $1.21B | +55.6% |
| FY2007 | Dec 31, 2007 | $779.77M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $610.70M | -37.3% |
| Q4 FY2021 | Dec 31, 2021 | $587.10M | – |
| Q3 FY2021 | Sep 30, 2021 | $794.00M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $485.70M | -75.4% |
| Q1 FY2021 | Mar 31, 2021 | $973.90M | -46.5% |
| Q4 FY2020 | Dec 31, 2020 | -$330.60M | -118.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.09B | -39.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.97B | +1.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.82B | +21.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.78B | +23.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.81B | +6.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.96B | +61.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.50B | -2.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.44B | -1.6% |
| Q3 FY2018 | Sep 30, 2018 | $1.70B | +2.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.21B | +1.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.53B | +49.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.47B | +65.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.65B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.20B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.02B | – |
| Q4 FY2016 | Dec 31, 2016 | $887.50M | – |
See a number that looks wrong?